Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 30, 2007
JNCI Journal of the National Cancer Institute 2007 99(21):1644; doi:10.1093/jnci/djm175
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/21/1644    most recent
djm175v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferretti, G.
Right arrow Articles by Cognetti, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferretti, G.
Right arrow Articles by Cognetti, F.
Related Collections
Right arrowRelated Article in JNCI
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Re: Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor–Targeted Therapy

Gianluigi Ferretti, Alessandra Felici, Francesco Cognetti

Affiliation of authors: Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy

Correspondence to: Gianluigi Ferretti, MD, PhD, Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy (e-mail: gia.fer@flashnet.it).

The first 10% of the full text of this article appears below.

In the Discussion section of their article, Arpino et al. (1) asserted that the antitumor effect of tamoxifen and human epidermal growth factor receptor (HER) inhibition "was lower when estrogen was present than when estrogen was absent." Estrogen-induced tumor growth is only . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
Grazia Arpino, Carolina Gutierrez, Heidi Weiss, Mothaffar Rimawi, Suleiman Massarweh, Lavina Bharwani, Sabino De Placido, C. Kent Osborne, and Rachel Schiff
J Natl Cancer Inst 2007 99: 694-705. [Abstract] [Full Text] [PDF]

Response to this Correspondence

Responses: Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy
Umberto Veronesi, Bernardo Bonanni, and Andrea Decensi
J Natl Cancer Inst 2007 99: 1644-1645. [Extract] [Full Text] [PDF]

Responses: Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy
Trevor J. Powles, Sue Ashley, Ian E. Smith, and Mitch Dowsett
J Natl Cancer Inst 2007 99: 1645-1646. [Extract] [Full Text] [PDF]